| scholarly article | Q13442814 |
| P50 | author | Assiamira Ferrara | Q37637594 |
| P2093 | author name string | Margaret R Karagas | |
| Alan Schned | |||
| Michael S Zens | |||
| Todd MacKenzie | |||
| P2860 | cites work | Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study | Q28219349 |
| Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure | Q30975525 | ||
| Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System | Q33288486 | ||
| Diabetes mellitus and risk of bladder cancer: a meta-analysis | Q36615062 | ||
| Urinary tract infections and reduced risk of bladder cancer in Los Angeles | Q37123550 | ||
| Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements | Q37375850 | ||
| Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models | Q37619049 | ||
| Diabetes mellitus type 2 - an independent risk factor for cancer? | Q37686371 | ||
| Fasting serum glucose level and cancer risk in Korean men and women | Q43943327 | ||
| Diabetes: diabetes therapy and cancer risk. | Q44268095 | ||
| Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study | Q45172056 | ||
| Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers | Q46422710 | ||
| Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. | Q47220430 | ||
| Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. | Q51501226 | ||
| Type 2 diabetes mellitus and risk of developing urinary incontinence. | Q51960569 | ||
| Body mass index, physical activity, and bladder cancer in a large prospective study. | Q53540020 | ||
| Urinary tract infection and risk of bladder cancer | Q71316031 | ||
| Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan | Q79137223 | ||
| Diabetes and cancer | Q84262739 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1552-1556 | |
| P577 | publication date | 2010-11-08 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Diabetes and risk of bladder cancer: evidence from a case-control study in New England | |
| P478 | volume | 117 |
| Q38374279 | Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review |
| Q36073447 | Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study' |
| Q36486802 | Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study |
| Q38262803 | Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review |
| Q33646525 | CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis |
| Q64980814 | Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. |
| Q50728227 | Comorbidities associated with bladder dysfunction. |
| Q34205117 | Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium |
| Q34069053 | Diabetes and cancer I: risk, survival, and implications for screening |
| Q36614839 | Diabetes and risk of bladder cancer among postmenopausal women in the Iowa Women's Health Study |
| Q43748015 | Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan |
| Q42644941 | Diabetes mellitus and cancer risk in a network of case-control studies |
| Q49372368 | Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. |
| Q36286678 | Diabetes mellitus and the risk of bladder cancer: an Italian case–control study |
| Q37280771 | Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies |
| Q85896441 | Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma |
| Q37972673 | Diabetes, cancer, and metformin: connections of metabolism and cell proliferation |
| Q53085995 | Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. |
| Q40649706 | Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. |
| Q37496102 | Human insulin does not increase bladder cancer risk |
| Q37153221 | Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus |
| Q55239950 | Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. |
| Q88149726 | Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence |
| Q35810977 | Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study |
| Q28707471 | Modeling temporal relationships in large scale clinical associations |
| Q45250550 | Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy |
| Q37730336 | Obesity, Diabetes and Cancer: A Mechanistic Perspective |
| Q38043808 | Phytochemicals and their impact on adipose tissue inflammation and diabetes. |
| Q38417421 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis |
| Q38721611 | Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis |
| Q38282651 | Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit |
| Q34522889 | Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. |
| Q36255885 | Risk of Malignant Neoplasms of Kidney and Bladder in a Cohort Study of the Diabetic Population in Taiwan With Age, Sex, and Geographic Area Stratifications |
| Q34353701 | Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies |
| Q38122640 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? |
| Q60050081 | The association between metabolic syndrome and bladder cancer susceptibility and prognosis: an updated comprehensive evidence synthesis of 95 observational studies involving 97,795,299 subjects |
| Q90473299 | The association between type 2 diabetes mellitus and bladder cancer risk among postmenopausal women |
| Q51240123 | The impact of type 2 diabetes mellitus on mortality in hospitalized female cancer patients in Taiwan. |
| Q36365241 | The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. |
| Q36001145 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
Search more.